Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367887 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
A Phase 2 study of Hepatitis C, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
- 20
- Study locations
NCT00367887: Completed Phase 2 study of Hepatitis C, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00367887 is a Phase 2 study of Hepatitis C that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 246 participants, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00367887, a Phase 2 study of Hepatitis C, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders).
Conditions Studied
Interventions
- DRUG Peg-Intron
- DRUG REBETOL
- DRUG HCV 796
Study Locations (20)
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Pasadena
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - San Francisco
- Pfizer Investigational Site - San Francisco
Florida
- Pfizer Investigational Site - Gainesville
- Pfizer Investigational Site - Miami
Massachusetts
- Pfizer Investigational Site - Boston
- Pfizer Investigational Site - Worcester
Minnesota
- Pfizer Investigational Site - Plymouth
- Pfizer Investigational Site - Saint Paul
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Georgia
- Pfizer Investigational Site - Atlanta
Kentucky
- Pfizer Investigational Site - Louisville
Michigan
- Pfizer Investigational Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00367887 record still lists
NCT00367887 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Peg-Intron is the first listed.
NCT00367887 names 20 study sites across 9 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00367887 about?
NCT00367887 is a clinical study titled "A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects". This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects ...
What is the current status of trial NCT00367887?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2006-10. Estimated completion is 2008-07.
What conditions does trial NCT00367887 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00367887?
The interventions under investigation include: Peg-Intron (DRUG), REBETOL (DRUG), HCV 796 (DRUG).
Who is sponsoring clinical trial NCT00367887?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00367887 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00367887's enrollment target sits among peer trials
246 40th of 106 higher than 67 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia